Jeong SH, Kim RB, Park SY, et al. - Using prognostic biomarker gene expression, researchers developed a nomogram that may assist in predicting the 5-year recurrence-free probability (RFP) of gastric cancer patients. They included 360 patients in the training data set to develop the predictive model and nomogram and used 420 patients from the validation data set to perform external validation. The nonrecurrence and recurrence groups were analyzed for the patients’ general variables and the gene expression levels of 10 prognostic biomarker candidates. Inclusion of age, gender, and the expression levels of F-actin capping protein α1 subunit, inorganic pyrophosphatase, octamer transcription factor-1, peroxiredoxin-4, gamma-enolase, and c-Myc, was done in the final nomogram. For the patients in the low-risk, intermediate-risk, high-risk and very-high-risk groups in the development cohort, the 5-year RFPs were 89%, 75%, 54%, and 32 %, respectively. The 5-year RFPs were 89%, 75%, 63%, and 60%, respectively, in the external validation cohort. Findings support the value of this newly developed nomogram using gene expression in predicting the 5-year RFP for gastric cancer patients after surgical treatment. This nomogram is expected to serve as a tool to aid in the therapeutic decision between endoscopic treatment and gastrectomy.